Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
Mar. 31, 2025	Mar. 31, 2024
Revenues:
Total revenues	$ 0	$ 235
Revenue, Product and Service [Extensible Enumeration]	License and Collaboration Revenues [Member]	License and Collaboration Revenues [Member]
Operating expenses:
Research and development	$ 11,814	$ 13,364
General and administrative	3,959	3,507
Total operating expenses	15,773	16,871
Loss from operations	(15,773)	(16,636)
Total other income (expense), net	892	1,149
Consolidated net loss	(14,881)	(15,487)
Net loss (gain) attributable to noncontrolling interest in Pangu BioPharma Limited	1	(4)
Net loss attributable to aTyr Pharma, Inc.	$ (14,880)	$ (15,491)
Net loss per share - basic	$ (0.17)	$ (0.23)
Net loss per share - diluted	$ (0.17)	$ (0.23)
Shares used in computing net loss per share, basic	86,485,126	66,080,593
Shares used in computing net loss per share, diluted	86,485,126	66,080,593

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Name:	us-gaap_EarningsPerShareBasic
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.